Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
National Cancer Institute
>>
Phase 1
Welcome,
Profile
Billing
Logout
All trials
Active industry trials
Active owner-sponsored trials
Active trials
Export
Download options
Which format:
PDF
Excel Chart
TSV
Phase
N/A
1
2
3
4
Trials
0
1
2
3
4
5
6
7
8
9
10
Ad-CCL21-DC
/ National Cancer Institute
4'-Thio-2'-Deoxycytidine
(TdCyd) / National Cancer Institute
Combotox
(Imtox19/Imtox22) / Montefiore Medical Center, National Cancer Institute, Abiogen
anti-CD22 CAR T
/ National Cancer Institute
anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells
/ National Cancer Institute
AdHER2/neu DC Vaccine
/ National Cancer Institute
BC8-SA
/ National Cancer Institute
CD123R(EQ)28zeta/EGFRt+ T cells
/ National Cancer Institute
EGFRvIII CAR
/ National Cancer Institute, Gilead
FCARH143
/ BMS, Fred Hutchinson Cancer Center, National Cancer Institute
FHVH-BCMA-T
/ National Cancer Institute
IgG-RFB4-SMPT-dgA
/ National Cancer Institute
JCAR018
/ BMS, National Cancer Institute
LMP744
/ Gibson Oncology
P30-EPS
/ Duke University, National Cancer Institute
Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta and Tyrosinase Related Protein 1
/ National Cancer Institute
anti-CD33 CAR T
/ City of Hope, National Cancer Institute
anti-GD2 CAR-T cell therapy
/ Bellicum, National Cancer Institute
neoantigen peptide vaccine
/ Mayo Clinic, National Cancer Institute
rHIgM12B7
/ National Cancer Institute, Mayo Clinic
recombinant human Hsp110-gp100 chaperone complex vaccine
/ National Cancer Institute, Roswell Park Comprehensive Cancer Center
yttrium Y 90 anti-CD19 Ab
(BU 12) / National Cancer Institute
